clinical trials

Sensei Biotherapeutics stock surged 230% after acquiring Faeth Therapeutics and securing $200M investment, expanding its oncology pipeline with PIKTOR therapy.

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.

12+ companies advance iPSC-derived NK cell therapies for cancer treatment. Century Therapeutics and Fate Therapeutics report promising clinical progress in this expanding immunotherapy field.

Human microbiome market expected to grow nearly fourfold to $3.27B by 2035, driven by advancing sequencing technology and 215+ therapeutic candidates in clinical development.

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.

BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.